TY - JOUR
T1 - Breast cancer therapies reduce risk of Alzheimer's disease and promote estrogenic pathways and action in brain
AU - Branigan, Gregory L.
AU - Torrandell-Haro, Georgina
AU - Chen, Shuhua
AU - Shang, Yuan
AU - Perez-Miller, Samantha
AU - Mao, Zisu
AU - Padilla-Rodriguez, Marco
AU - Cortes-Flores, Helena
AU - Vitali, Francesca
AU - Brinton, Roberta Diaz
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023/11/17
Y1 - 2023/11/17
N2 - Worldwide, an ever-increasing number of women are prescribed estrogen-modulating therapies (EMTs) for the treatment of breast cancer. In parallel, aging of the global population of women will contribute to risk of both breast cancer and Alzheimer's disease. To address the impact of anti-estrogen therapies on risk of Alzheimer's and neural function, we conducted medical informatic and molecular pharmacology analyses to determine the impact of EMTs on risk of Alzheimer's followed by determination of EMT estrogenic mechanisms of action in neurons. Collectively, these data provide both clinical and mechanistic data indicating that select EMTs exert estrogenic agonist action in neural tissue that are associated with reduced risk of Alzheimer's disease while simultaneously acting as effective estrogen receptor antagonists in breast.
AB - Worldwide, an ever-increasing number of women are prescribed estrogen-modulating therapies (EMTs) for the treatment of breast cancer. In parallel, aging of the global population of women will contribute to risk of both breast cancer and Alzheimer's disease. To address the impact of anti-estrogen therapies on risk of Alzheimer's and neural function, we conducted medical informatic and molecular pharmacology analyses to determine the impact of EMTs on risk of Alzheimer's followed by determination of EMT estrogenic mechanisms of action in neurons. Collectively, these data provide both clinical and mechanistic data indicating that select EMTs exert estrogenic agonist action in neural tissue that are associated with reduced risk of Alzheimer's disease while simultaneously acting as effective estrogen receptor antagonists in breast.
KW - Cancer
KW - Neurology
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=85176608278&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85176608278&partnerID=8YFLogxK
U2 - 10.1016/j.isci.2023.108316
DO - 10.1016/j.isci.2023.108316
M3 - Article
AN - SCOPUS:85176608278
SN - 2589-0042
VL - 26
JO - iScience
JF - iScience
IS - 11
M1 - 108316
ER -